Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quantum BioPharmaSTU:0K91 -6.84%38 Days Inventory is 0.00 as of Mar. 2026. GuruFocus rates STU:0K91 with a GF Score™ of 38/100. The stock has 5 warning signs investors should review. Among 638 Biotechnology companies, Quantum BioPharma ranks worse than 156739.66% on this metric.
The historical rank and industry rank for Quantum BioPharma's Days Inventory or its related term are showing as below:
During the past 11 years, Quantum BioPharma's highest Days Inventory was 140.47. The lowest was 140.47. And the median was 140.47.
STU:0K91's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 183.195 * Ranked among companies with meaningful Days Inventory only.
Quantum BioPharma's Days Inventory
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Quantum BioPharma's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Quantum BioPharma (STU:0K91) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Quantum BioPharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Quantum BioPharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Quantum BioPharma Days Inventory Related Terms
Quantum BioPharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Quantum BioPharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0K91 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Quantum BioPharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quantum BioPharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quantum BioPharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Quantum BioPharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quantum BioPharma (STU:0K91) has a Days Inventory of 0.00 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Quantum BioPharma and its competitors. Over the past decade, Quantum BioPharma's Days Inventory has ranged from 140.47 to 140.47. According to the industry distribution chart, Quantum BioPharma ranks #999999 out of 638 companies in the Biotechnology industry.
Is Quantum BioPharma's Days Inventory too high?
Quantum BioPharma's current Days Inventory is 0.00. Over the past 10 years, this metric has ranged from a low of 140.47 to a high of 140.47. Based on the distribution chart, Quantum BioPharma ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Quantum BioPharma has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Quantum BioPharma's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Quantum BioPharma ranks #999999 out of 638 companies for Days Inventory. This places Quantum BioPharma in the lower half of its industry. The industry median Days Inventory is 183.20. Historically, Quantum BioPharma's own Days Inventory has ranged from 140.47 to 140.47 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Quantum BioPharma and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quantum BioPharma's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quantum BioPharma stock overvalued right now?
Quantum BioPharma (STU:0K91) has a current Days Inventory of 0.00. The current Days Inventory is 0.00. Quantum BioPharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Quantum BioPharma (STU:0K91), the current Days Inventory is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
38GF Score
Get the complete analysis for STU:0K91
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0K91 has been successfully added to your 
